Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.45 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1558279 | 0.86 | HTR1A (0.36) | PRMT5 | |
| SCHEMBL31192638 | 0.85 | TRPV3 (0.52) | GPR119PRMT5TRPV3 | |
| SCHEMBL10324303 | 0.85 | TRPV3 (0.52) | GPR119PRMT5TRPV3 | |
| SCHEMBL3604191 | 0.84 | GPR119 (0.53) | GPR119 | |
| SCHEMBL25279836 | 0.84 | TRPV3 (0.48) | GPR119PRMT5TRPV3 | |
| SCHEMBL29079757 | 0.84 | TRPV3 (0.48) | GPR119PRMT5TRPV3 | |
| SCHEMBL1556591 | 0.82 | GPR119 (0.54) | GPR119 | |
| SCHEMBL30378233 | 0.82 | GPR119 (0.47) | GPR119PRMT5STS | |
| SCHEMBL1557797 | 0.80 | GPR119 (0.57) | GPR119 | |
| SCHEMBL28759751 | 0.79 | GPR119 (0.57) | GPR119PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. | 2012-07-19 | — | — | US | disclosed |
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. | 2012-07-19 | — | — | US | disclosed |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2303859-A2 | ARYL GPR119 AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010008739-A2 | ARYL GPR119 AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184572-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | GPR119, GPR27, GPR65 | GPR119 1/4885PRMT5 3932/4885TRPV3 1124/4885 |
| US-20110294836-A1 | ARYL GPR119 AGONISTS AND USES THEREOF | GPR119, GPR27, GPR65 | GPR119 1/4885PRMT5 3932/4885TRPV3 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.